BACKGROUND AND AIMS: Endotherapy (ET) has replaced surgery as the first-line treatment of high-grade dysplasia (HGD)/superficial ECA (ECAs) from Barrett's oesophagus (BO). However, long-term follow-up and predictive factors of relapse are not so well studied. The aim of the following study was to evaluate the efficiency of ET for treatment of HGD/ECAs and to determine factors of long-term efficiency. METHODS: ET procedures were manually reported and registered in a hospital data base from March 2000 to July 2010. Inclusion criteria were HGD/ECA on pre-resection biopsies, complete histological and sufficient oncological resection of HGD/ECAs, and complete macroscopic resection of metaplastic BO. Sixty patients (53 men, mean age = 65 years) were included. RESULTS: Median follow-up was 66 months [range 42-80]. Complete eradication of residual histological metaplastic BO occurred in 29 patients (48 %). Relapse rate at 36 months was 16.6 % (n = 10) and was unchanged at 60 months of follow-up. There was only one relapse (3.4 %) in case of complete eradication of metaplastic BO and 9 (31 %) in case of incomplete eradication. In univaried and multi-varied analysis, complete eradication of metaplastic BO (p < 0.05) and BO length <5 cm (p < 0.05) were predictive of neoplastic BO non relapse. The length of BO remained a prognostic factor for disease-free survival (DFS). When these preponderant data were cancelled out in multi-varied analysis, complete eradication of BO was a prognostic factor for DFS (p < 0.05). CONCLUSION: Complete histological eradication of BO by ET significantly decreases the rate of neoplasia relapse.
BACKGROUND AND AIMS: Endotherapy (ET) has replaced surgery as the first-line treatment of high-grade dysplasia (HGD)/superficial ECA (ECAs) from Barrett's oesophagus (BO). However, long-term follow-up and predictive factors of relapse are not so well studied. The aim of the following study was to evaluate the efficiency of ET for treatment of HGD/ECAs and to determine factors of long-term efficiency. METHODS: ET procedures were manually reported and registered in a hospital data base from March 2000 to July 2010. Inclusion criteria were HGD/ECA on pre-resection biopsies, complete histological and sufficient oncological resection of HGD/ECAs, and complete macroscopic resection of metaplastic BO. Sixty patients (53 men, mean age = 65 years) were included. RESULTS: Median follow-up was 66 months [range 42-80]. Complete eradication of residual histological metaplastic BO occurred in 29 patients (48 %). Relapse rate at 36 months was 16.6 % (n = 10) and was unchanged at 60 months of follow-up. There was only one relapse (3.4 %) in case of complete eradication of metaplastic BO and 9 (31 %) in case of incomplete eradication. In univaried and multi-varied analysis, complete eradication of metaplastic BO (p < 0.05) and BO length <5 cm (p < 0.05) were predictive of neoplastic BO non relapse. The length of BO remained a prognostic factor for disease-free survival (DFS). When these preponderant data were cancelled out in multi-varied analysis, complete eradication of BO was a prognostic factor for DFS (p < 0.05). CONCLUSION: Complete histological eradication of BO by ET significantly decreases the rate of neoplasia relapse.
Authors: K Nadine Phoa; Roos E Pouw; Frederike G I van Vilsteren; Carine M T Sondermeijer; Fiebo J W Ten Kate; Mike Visser; Sybren L Meijer; Mark I van Berge Henegouwen; Bas L A M Weusten; Erik J Schoon; Rosalie C Mallant-Hent; Jacques J G H M Bergman Journal: Gastroenterology Date: 2013-03-28 Impact factor: 22.682
Authors: Roos E Pouw; Stefan Seewald; Joep J Gondrie; Pierre H Deprez; Hubert Piessevaux; Heiko Pohl; Thomas Rösch; Nib Soehendra; Jacques J Bergman Journal: Gut Date: 2010-06-04 Impact factor: 23.059
Authors: K Nadine Phoa; Roos E Pouw; Raf Bisschops; Oliver Pech; Krish Ragunath; Bas L A M Weusten; Brigitte Schumacher; Bjorn Rembacken; Alexander Meining; Helmut Messmann; Erik J Schoon; Liebwin Gossner; Jayan Mannath; C A Seldenrijk; Mike Visser; Toni Lerut; Stefan Seewald; Fiebo J ten Kate; Christian Ell; Horst Neuhaus; Jacques J G H M Bergman Journal: Gut Date: 2015-03-02 Impact factor: 23.059
Authors: Oliver Pech; Elfriede Bollschweiler; Hendrik Manner; Jessica Leers; Christian Ell; Arnulf H Hölscher Journal: Ann Surg Date: 2011-07 Impact factor: 12.969
Authors: Benjamin J Vaccaro; Susana Gonzalez; John M Poneros; Peter D Stevens; Kristina M Capiak; Charles J Lightdale; Julian A Abrams Journal: Dig Dis Sci Date: 2011-04-06 Impact factor: 3.199
Authors: P Thomas; C Doddoli; P Neville; J Pons; P Lienne; R Giudicelli; M Giovannini; J F Seitz; P Fuentes Journal: Eur J Cardiothorac Surg Date: 1996 Impact factor: 4.191
Authors: M Giovannini; E Bories; C Pesenti; V Moutardier; G Monges; C Danisi; B Lelong; J R Delpero Journal: Endoscopy Date: 2004-09 Impact factor: 10.093
Authors: Sébastien Godat; Mariola Marx; Fabrice Caillol; Maxime Robert; Aurélie Autret; Erwan Bories; Christian Pesenti; Jean Philippe Ratone; Alain Schoepfer; Flora Poizat; Marc Giovannini Journal: Ann Gastroenterol Date: 2021-12-06